scholarly journals The Relationship Between Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma

Author(s):  
Misael Uribe ◽  
Jess Romn-Sandoval ◽  
Norberto C. ◽  
Nahum Mndez-Snchez
Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 516
Author(s):  
Tomomi Kogiso ◽  
Katsutoshi Tokushige

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and can develop into hepatocellular carcinoma (HCC). The incidence of NAFLD-related HCC, which is accompanied by life-threatening complications, is increasing. Advanced fibrosis and lifestyle-related and metabolic comorbidities, especially obesity and diabetes mellitus, are associated with HCC development. However, HCC is also observed in the non-cirrhotic liver. Often, diagnosis is delayed until the tumor is relatively large and the disease is advanced; an effective screening or surveillance method is urgently required. Recently, the NAFLD/nonalcoholic steatohepatitis (NASH) guidelines of Japan were revised to incorporate new strategies and evidence for the management and surveillance of NAFLD/NASH. Fibrosis must be tested for noninvasively, and the risk of carcinogenesis must be stratified. The treatment of lifestyle-related diseases is expected to reduce the incidence of NAFLD and prevent liver carcinogenesis.


Medicine ◽  
2017 ◽  
Vol 96 (39) ◽  
pp. e8164 ◽  
Author(s):  
Xiao-Long Yu ◽  
Long Shu ◽  
Xiao-Ming Shen ◽  
Xiao-Yan Zhang ◽  
Pei-Fen Zheng

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Jihane N. Benhammou ◽  
Elizabeth S. Aby ◽  
Gayaneh Shirvanian ◽  
Kohlett Manansala ◽  
Shehnaz K. Hussain ◽  
...  

2019 ◽  
Vol 35 (5) ◽  
pp. 862-869 ◽  
Author(s):  
Maki Tobari ◽  
Etsuko Hashimoto ◽  
Makiko Taniai ◽  
Kazuhisa Kodama ◽  
Tomomi Kogiso ◽  
...  

Medicina ◽  
2019 ◽  
Vol 55 (9) ◽  
pp. 600 ◽  
Author(s):  
Oral ◽  
Sahin ◽  
Turker ◽  
Kocak

Background and objectives: Nonalcoholic fatty liver disease (NAFLD) is associated with multiple factors such as hypertension, diabetes, dyslipidemia, obesity, and hyperuricemia. We aim to investigate the relationship between uric acid and NAFLD in a non-obese and young population. Materials and Methods: This study was performed in January 2010–2019 with a group of 367 (225 patients in the NAFLD group and 142 in the control group) patients with liver biopsy-proven NAFLD or no NAFLD. Patients with NAFLD were classified according to the percentage of steatosis as follows, group I had 1–20% and group II >20%. Demographic, clinical, and laboratory (biochemical parameters) features were collected retrospectively. Results: The mean body mass index (BMI) and age of the patients were 26.41 ± 3.42 and 32.27 ± 8.85, respectively. The BMI, homeostatic model of assessment (HOMA-IR), and uric acid (UA) values of the NAFLD group were found to be significantly higher than those of the controls. A positive correlation was found between the NAFLD stage and UA. The following factors were independently associated with NAFLD: BMI, HOMA-IR, and UA. In addition, the cut-off value of UA was 4.75 mg/dl with a sensitivity of 45.8% and a specificity of 80.3%. Conclusions: UA is a simple, non-invasive, cheap, and useful marker that may be used to predict steatosis in patients with NAFLD.


Sign in / Sign up

Export Citation Format

Share Document